Organisation paid for research Program year 2025 Source: CMS Open Payments

Pas Research

Neither a doctor nor a teaching hospital

Research payments

$5,324,382

306 payments

Through program year 2025, Pas Research is reported as receiving $5,324,382 in research payments, across 306 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$1,490,389	34
2024	Research	$1,020,327	91
2023	Research	$1,736,415	69
2022	Research	$363,983	46
2021	Research	$630,979	57
2020	Research	$82,290	9

Breakdown

Who paid Research payments · program years 2020–2025

DiaSorin Molecular LLC $2,662,093 6 payments
GlaxoSmithKline, LLC. $1,557,180 163 payments
Pfizer Inc. $930,448 120 payments
Rapid Pathogen Screening, Inc. $86,068 4 payments
Amgen Inc. $37,019 4 payments
Lupin Inc. $34,038 2 payments
Lumos Diagnostics, Inc. $10,115 5 payments
Moderna TX, Inc. $5,080 1 payment
Takeda Pharmaceuticals U.S.A., Inc. $2,342 1 payment

Studies the money was for Research payments · program years 2020–2025

NES Flu A/B & COVID-19 Clinical Study (Project DD20-012) $812,088 2 payments
NES Flu A/B (Project DD20-012) Clinical Study $700,666 1 payment
A Phase II, Single-Blind, Randomized, Controlled Study to Evaluate the $604,343 58 payments
NES Flu A/B (Project DD20-012) $589,202 1 payment
A Multi-Site Clinical Evaluation of the LIAISON NES Group A Strep (GAS) Assay in Symptomatic Patients (Project DD22-001) $560,138 2 payments
Phase Iiib, Observer-Blind, Randomized, Placebo-Controlled, Multi-Cent $443,763 55 payments
A Phase 3 Randomized Activecontrolled Observerblinded Trial to Assess the Safety Tolerability and Immunogenicity of Menabcwy in Healthy Participants 10 to 26 Years of Age $356,094 32 payments
A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $297,707 38 payments
A Phase 3A, Observer-Blind, Randomized, Controlled Study to Demonstrat $284,154 10 payments
A Master Phase 123 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b2 Rna Based Vaccine Candidates in Healthy Children $197,195 24 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.